Comparison of methods for calculating rectal dose after 125I prostate brachytherapy implants

被引:12
|
作者
Hilts, M
Spadinger, I
Keyes, M
机构
[1] BC Canc Agcy, Dept Phys Med, Vancouver Canc Ctr, Vancouver, BC V6R 2B6, Canada
[2] BC Canc Agcy, Dept Radiat Oncol, Vancouver Canc Ctr, Vancouver, BC V6R 2B6, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 53卷 / 03期
关键词
rectal dose; prostate brachytherapy; post-implant dosimetry;
D O I
10.1016/S0360-3016(02)02798-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare several different methods of calculating the rectal dose and examine how accurately they represent rectal dose surface area measurements and, also, their practicality for routine use. Methods and Materials: This study comprised 55 patients, randomly selected from 295 prostate brachytherapy patients implanted at the Vancouver Cancer Center between 1998 and 2000. All implants used a nonuniform loading of 0.33 mCi (NIST-99) I-125 seeds and a prescribed dose of 144 Gy. Pelvic CT scans were obtained for each patient similar to30 days after implantation. For the purposes of calculating the rectal dose, several structures were contoured on the CT images: (1) a 1-mm-thick anterior rectal wall, (2) the anterior half rectum, and (3) the whole rectum. Point doses were also obtained along the anterior rectal surface. The thin wall contour provided a surrogate for a dose-surface histogram (DSH) and was our reference standard rectal dose measurement. Alternate rectal dose measurements (volume, surface area, and length of rectum receiving a dose of interest [DOI] of greater than or equal to144 Gy and 216 Gy, as well as point dose measures) were calculated using several methods (VariSeed software) and compared with the surrogate DSH measure (SA(DOI)). Results: The best correlation with SA(144Gy) was the dose volumes (whole or anterior half rectum) (R = 0.949). The length of rectum receiving greater than or equal to144 Gy also correlated well with SA(144Gy) (R greater than or equal to0.898). Point dose measures, such as the average and maximal anterior dose, correlated poorly with SA(144Gy) (R less than or equal to0.649). The 216-Gy measurements supported these results. In addition, dose-volume measurements were the most practical (similar to6 min/patient), with our surrogate DSH the least practical (similar to20 min/patient). Conclusion: Dose-volume measurements for the whole or anterior half rectum, because they were the most practical measures and best represented the DSH measurements, should be considered a standard method of reporting the rectal dose when calculating the DSH is not practical. Average or maximal anterior rectal doses are not reliable indicators of surface area dosimetry. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:775 / 785
页数:11
相关论文
共 50 条
  • [31] Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer
    Kubo, Katsumaro
    Wadasaki, Koichi
    Kimura, Tomoki
    Murakami, Yuji
    Kajiwara, Mitsuru
    Teishima, Jun
    Matsubara, Akio
    Nagata, Yasushi
    JOURNAL OF RADIATION RESEARCH, 2018, 59 (05) : 649 - 655
  • [32] Comparison of methods for preparation of 125I brachytherapy source cores for the treatment of eye cancer
    Manolkar, RB
    Sane, SU
    Pillai, KT
    Majali, MA
    APPLIED RADIATION AND ISOTOPES, 2003, 59 (2-3) : 145 - 150
  • [33] Dose optimization in 125I permanent prostate seed implants using the Monte Carlo method
    Reis, Juraci P.
    Menezes, Artur F.
    Souza, Edmilson M.
    Facure, Alessandro
    Medeiros, Jose A. C. C.
    Silva, Ademir X.
    COMPUTER PHYSICS COMMUNICATIONS, 2012, 183 (04) : 847 - 852
  • [34] Permanent 125I prostate brachytherapy for castration-resistant prostate cancer
    Ding, Xue-Fei
    Huang, Tian-Bao
    Gao, Ying
    Lu, Sheng-Ming
    Tao, Hua-Zhi
    Xu, Jia-Nan
    Xu, Yao-Zong
    Wang, Fei
    Zhou, Yu-Quan
    Zhou, Guang-Chen
    Luan, Yang
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (02) : 278 - 283
  • [35] Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy
    Tanaka O.
    Hayashi S.
    Matsuo M.
    Nakano M.
    Kubota Y.
    Maeda S.
    Ohtakara K.
    Deguchi T.
    Hoshi H.
    Radiation Medicine, 2007, 25 (7): : 329 - 334
  • [36] A PRELIMINARY STUDY OF THE EXTERNAL DOSE RATES DISTRIBUTION FOR PATIENTS WITH PROSTATE PERMANENT 125I IMPLANTS
    Vasile, Madalina
    Vasile, G.
    Duliu, O. G.
    ROMANIAN REPORTS IN PHYSICS, 2011, 63 (01) : 190 - 195
  • [37] Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131CS and 125I for prostate permanent implant brachytherapy
    Sahgal, Arjun
    Jabbari, Siavash
    Chen, Josephine
    Pickett, Barbie
    Roach, Mack, III
    Weinberg, Vivian
    Hsu, I-Chow
    Pouliot, Jean
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : 247 - 254
  • [38] INTERSEED EFFECTS ON DOSE FOR I-125 BRACHYTHERAPY IMPLANTS
    MEIGOONI, AS
    MELI, JA
    NATH, R
    MEDICAL PHYSICS, 1992, 19 (02) : 385 - 390
  • [39] A COMPARISON OF THE DOSIMETRY AND VISIBILITY OF 125I ONCOSEED MODEL 9011 AND 6711 PROSTATE BRACHYTHERAPY SOURCES
    Roberts, G.
    Al-Qaisieh, B.
    Bownes, P.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S543 - S543
  • [40] A COMPARISON OF THE DOSIMETRY AND VISIBILITY OF 125I ONCOSEED MODEL 9011 AND 6711 PROSTATE BRACHYTHERAPY SOURCES
    Roberts, G.
    Al-Qaisieh, B.
    Bownes, P.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S543 - S543